Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Real-world evaluation of teclistamab for relapsed/refractory myeloma from IMWG finds ORR 67% (55% VGPR or better); 6-month PFS and OS 53% and 73%; patients with prior BCMA had lower ORR (58.3 vs 74.0%) and PFS (6-mo PFS 43% vs. 63%).”
Authors: Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Brian Durie, Saad Usmani, Thomas Martin, Yi Lin et al.
More posts featuring Robert Orlowski.
